You have not yet registered? Get your account for free.
Forgot Password? We will send you a reset link
20 April 2021
T3D Therapeutics, Inc.: T3D Therapeutics Announces First Patient Dosed in its Phase 2 Study of T3D-959 for the Treatment of Mild to Moderate Alzheimer’s Disease